NDA 016785 · Leadiant Biosci INC
Matulane
Procarbazine Hydrochloride · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Sep 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1969
Jul 22, 1969
Approved uses
1
Original approval plus efficacy supplements
Registered trials
82
29 Phase 3, 5 recruiting
FAERS reports
4,792
1,270 serious, 323 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 9, 2026.
MATULANE is indicated for use in combination with other anticancer drugs for the treatment of Stage III or Stage IV Hodgkin Lymphoma. MATULANE is an alkylating drug indicated for use in combination with other anticancer drugs for the treatment of Stage III or Stage IV Hodgkin Lymphoma. ( 1 )
Mechanism: The precise mode of cytotoxic action of procarbazine has not been clearly defined. After metabolic activation, procarbazine may inhibit the transmethylation of methyl groups of methionine into transfer RNA (t-RNA). The unavailability of t-RNA prevents protein synthesis, and consequently prevents DNA and RNA synthesis. Procarbazine may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which directly damage DNA through an alkylation reaction.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 22, 1969 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- MATULANE · PROCARBAZINE HYDROCHLORIDE EQ 50MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Procarbazine" as an intervention, any sponsor and status, largest first.
- Combination Chemotherapy in Treating Young Patients With Hodgkin's LymphomaPivotal-lookingCompleted
Christine Mauz-KörholzAcademic, hospital or other
NCT00433459 · 2,134 participants · Start Jan 2007 · Primary completion Jan 2013
Drug: cyclophosphamide; dacarbazine and 4 more · For: Lymphoma
Sites: Giessen, Germany; Edinburgh, United Kingdom
- Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's LymphomaPivotal-lookingStatus unknown
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00433433 · 1,952 participants · Start Oct 2006 · Primary completion Dec 2011
Drug: ABVD q4 weeks; BEACOPP escalated q3 weeks · For: Lymphoma
Sites: Nijmegen, Netherlands
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05675410 · 1,875 participants (planned) · Start May 11, 2023 · Primary completion Apr 28, 2031
Drug: Bleomycin Sulfate; Brentuximab Vedotin and 11 more · For: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 419 sites in all
- HD21 for Advanced StagesPivotal-lookingStatus unknown
University of CologneAcademic, hospital or other
NCT02661503 · 1,500 participants · Start Jul 2016 · Primary completion Dec 2022
Drug: Bleomycin; Etoposide and 8 more · For: Classical Hodgkin Lymphoma
Sites: Cologne, Germany
- HD11 for Intermediate StagesPivotal-lookingCompleted
University of CologneAcademic, hospital or other
NCT00264953 · 1,395 participants · Start May 1998 · Primary completion Jan 2003
Drug: Adriamycin; Bleomycin and 6 more · For: Hodgkin´s Lymphoma
- Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin LymphomaPivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT00678327 · 1,202 participants · Start Aug 29, 2008 · Primary completion Jan 31, 2016
Drug: bleomycin sulfate; filgrastim and 9 more · For: Lymphoma
Sites: Southampton, United Kingdom
- Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's LymphomaPivotal-lookingActive, not recruiting
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00379041 · 1,158 participants (planned) · Start Sep 1, 1993 · Primary completion Oct 1, 1998
Drug: bleomycin sulfate; doxorubicin hydrochloride and 5 more · For: Lymphoma
- HD17 for Intermediate Stage Hodgkin LymphomaPivotal-lookingCompleted
University of CologneAcademic, hospital or other
NCT01356680 · 1,100 participants · Start Jan 13, 2012 · Primary completion Mar 21, 2020
Drug: BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone); ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) · For: Hodgkin Lymphoma
Sites: Cologne, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea1,054
- fatigue934
- vomiting327
- constipation296
- platelet count decreased257
- white blood cell count decreased244
- headache198
- decreased appetite194
- rash173
- diarrhoea147
- neutropenia147
- blood count abnormal132
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 7 |
| 2008 | 5 |
| 2009 | 5 |
| 2010 | 45 |
| 2011 | 136 |
| 2012 | 250 |
| 2013 | 71 |
| 2014 | 55 |
| 2015 | 201 |
| 2016 | 245 |
| 2017 | 592 |
| 2018 | 555 |
| 2019 | 348 |
| 2020 | 318 |
| 2021 | 233 |
| 2022 | 355 |
| 2023 | 344 |
| 2024 | 358 |
| 2025 | 345 |
| 2026 | 311 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Matulane (Procarbazine HCl)
2024 spending
$1.9M
Beneficiaries
228
575 claims
Per beneficiary
$8,181
$130.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,356,378 |
| 2021 | $1,319,228 |
| 2022 | $1,661,437 |
| 2023 | $1,679,771 |
| 2024 | $1,865,330 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
Borchmann P, Ferdinandus J, Schneider G, et al. · Lancet 2024 · Multicenter Study, Clinical Trial, Phase III
- Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
Buckner JC, Shaw EG, Pugh SL, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Randomized Controlled Trial
- Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
McBain C, Lawrie TA, Rogoziska E, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
André MPE, Girinsky T, Federico M, et al. · J Clin Oncol 2017 · Clinical Trial, Phase III, Multicenter Study
- Hodgkin Lymphoma in Adults.
Bröckelmann PJ, Eichenauer DA, Jakob T, et al. · Dtsch Arztebl Int 2018 · Systematic Review
- Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Cairncross G, Wang M, Shaw E, et al. · J Clin Oncol 2013 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Leadiant Biosci INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.